TROVAN/ZITHROMAX COMPLIANCE PAK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TROVAN/ZITHROMAX COMPLIANCE PAK (TROVAN/ZITHROMAX COMPLIANCE PAK).
Trovafloxacin inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication. Azithromycin binds to 50S ribosomal subunit, inhibiting protein synthesis.
| Metabolism | Trovafloxacin: Primarily hepatic via glucuronidation and CYP450 (minimal). Azithromycin: Hepatic metabolism (demethylation); mainly excreted unchanged in bile. |
| Excretion | Trovafloxacin: 43% renal (unchanged), 47% fecal (unchanged + metabolites). Alatrofloxacin: prodrug converted to trovafloxacin. Azithromycin: 12% renal unchanged, 87% biliary/fecal as unchanged drug and metabolites. |
| Half-life | Trovafloxacin: terminal t1/2 ~9-12 hours (allows once-daily dosing). Azithromycin: terminal t1/2 ~68 hours (tissue accumulation enables once-daily 5-day regimen). |
| Protein binding | Trovafloxacin: 70% bound (albumin). Azithromycin: 7-50% (concentration-dependent, mainly to alpha-1-acid glycoprotein). |
| Volume of Distribution | Trovafloxacin: Vd ~1.3 L/kg (extensive tissue distribution). Azithromycin: Vd ~31 L/kg (extreme tissue uptake, e.g., lung, prostate). |
| Bioavailability | Trovafloxacin (oral): 87-95%. Alatrofloxacin (IV): prodrug 100% converted to trovafloxacin. Azithromycin (oral): 37% (reduced by food, take 1h before or 2h after meals); not available IV in this Pak. |
| Onset of Action | Oral trovafloxacin: peak effect in 1-2 hours; IV alatrofloxacin: immediate, conversion complete in 30 min. Azithromycin: peak effect in 2-3 hours oral; IV not in this Pak. |
| Duration of Action | Trovafloxacin: 24 hours (once-daily). Azithromycin: serum levels decline over 5 days; tissue levels persist 5-7 days (beyond last dose). |
Trovan (trovafloxacin/alatrofloxacin) 200 mg IV once daily, then oral trovafloxacin 200 mg once daily; Zithromax (azithromycin) 500 mg IV/oral once daily for 2 days, then 500 mg oral once daily for 7-10 days.
| Dosage form | FOR SUSPENSION, TABLET |
| Renal impairment | Trovan: No adjustment for mild-moderate renal impairment; CrCl <30 mL/min: reduce dose to 100 mg IV/oral once daily. Zithromax: No adjustment for mild-moderate impairment; severe renal impairment (CrCl <10 mL/min): use with caution, no specific dose recommendations. |
| Liver impairment | Trovan: Child-Pugh Class A: no adjustment; Class B/C: reduce dose to 100 mg once daily. Zithromax: Child-Pugh Class A: no adjustment; Class B/C: limited data, use with caution; no specific dose adjustment recommended. |
| Pediatric use | Trovan: Not FDA-approved for children <18 years; avoid use due to arthropathy risk. Zithromax: For children >6 months: 10 mg/kg IV/oral once daily (max 500 mg) for 1 day, then 5 mg/kg once daily (max 250 mg) for 4 days; alternatively, 30 mg/kg as a single oral dose (max 1500 mg) for acute otitis media. |
| Geriatric use | Trovan: No specific dose adjustment; monitor renal function and for QT prolongation. Zithromax: No specific dose adjustment; increased risk of torsades de pointes, monitor ECG and electrolytes; consider lower dose if renal impairment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TROVAN/ZITHROMAX COMPLIANCE PAK (TROVAN/ZITHROMAX COMPLIANCE PAK).
| Breastfeeding | Trovafloxacin: Excreted into breast milk; unknown M/P ratio. Avoid due to potential arthropathy in nursing infants. Azithromycin: Excreted into breast milk; M/P ratio approximately 0.75-1.5. Compatible with breastfeeding, but monitor infant for diarrhea, rash, or yeast infection. |
| Teratogenic Risk | TROVAN (trovafloxacin) is pregnancy category C; animal studies show fetal toxicity but no well-controlled human studies. Avoid in first trimester due to fluoroquinolone class effect on cartilage. ZITHROMAX (azithromycin) is pregnancy category B; no evidence of fetal harm in animal studies, but human data limited. Preferred over fluoroquinolones in pregnancy if indicated. |
■ FDA Black Box Warning
Trovafloxacin: Increased risk of hepatotoxicity, including fatal liver injury, limiting use to life-threatening infections in hospitalized patients.
| Serious Effects |
Trovafloxacin: Known hypersensitivity, prior hepatotoxicity from trovafloxacin, severe hepatic impairment. Azithromycin: Hypersensitivity to macrolides, history of cholestatic jaundice/hepatic dysfunction with azithromycin, concomitant use with pimozide or ergotamine.
| Precautions | Trovafloxacin: hepatotoxicity with liver failure, CNS effects, QT prolongation. Azithromycin: QT prolongation, hepatotoxicity, severe allergic reactions, Clostridioides difficile diarrhea. |
Loading safety data…
| Fetal Monitoring | Monitor maternal liver function and ECG (trovafloxacin risk of hepatotoxicity and QT prolongation). Fetal ultrasound for anomalies if first-trimester exposure to trovafloxacin. Assess infant for jaundice, diarrhea, and somnolence. |
| Fertility Effects | Azithromycin: No documented effect on fertility in animal studies. Trovafloxacin: High doses in animals reduced spermatogenesis; clinical relevance unknown. Use caution in couples planning pregnancy. |